Vir Biotechnology, Inc..
VIR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company develops therapeutic antibodies, T cell enhancers, and innate immunity modulators. Its pipeline incl...Show More
Better Health for All
30
Vir Biotechnology's core business is entirely focused on developing transformative medicines to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases, for which solutions are non-existent or inadequate.
1
The company aims to address diseases of considerable public health importance, such as HIV, Hepatitis B/D, Influenza, and HPV-related cancers, with no evidence of harmful products.
2
Vir launched in 2017 and has consistently focused on health benefits.
3
The company's pipeline includes investigational vaccines for HIV, tuberculosis, and malaria, demonstrating a strong focus on prevention.
4
Vir received a $10 million grant from the Bill & Melinda Gates Foundation for T cell vaccine development and has a potential total investment of up to $1 billion from BARDA for influenza and other infectious disease candidates.
5
During health crises, Vir contributed sotrovimab for COVID-19 and co-discovered ansuvimab-zykl for Ebola, and has a contract for pandemic preparedness.
6
Vir supported over 20 organizations in 2022 dedicated to advancing education and care for people living with infectious diseases and promoting equity in underserved communities.
7
Since 2020, it has run a mentorship program at SFSU targeting underrepresented groups and expanded its Biotechnology STEM Scholars program in 2022 by providing full-ride scholarships to underrepresented students.
8
Clinical trials aim to include patients from varied backgrounds.
9
However, Vir does not currently have an expanded access program for any of its investigational products, and its patent strategy includes in-licensing innovative technology platforms and novel clinical assets from other companies.
10
Fair Money & Economic Opportunity
0
Vir Biotechnology, Inc. is an immunology company focused on infectious diseases, not a financial institution.
1
Therefore, most KPIs related to financial services are not applicable. The company does not offer lending or deposit services to consumers, nor does it have APRs, fee structures, or loan books to evaluate.
2
It does not provide debt products or operate financial service access points.
3
While the company manages personal information and provides data access rights to individuals for their personal data, and makes healthcare pricing data available to researchers, this is not related to customer financial data portability or open banking APIs.
4
The company's diversity, equity, and inclusion efforts and support for public health initiatives are not financial inclusion programs.
5
There is no evidence of financial literacy programs or profit reinvestment in community finance.
6
Fair Pay & Worker Respect
20
The company's median CEO to median employee pay ratio was 96:1 in 2020.
1
Its employee engagement score was 84% in 2020, a 6% rise from 2019.
2
The voluntary employee turnover rate averaged 4.1% over five years from 2016 to 2020.
3
The company pays 100% of health insurance premiums for its employees and their families.
4
There is one documented labor-law violation incident, a lawsuit filed on October 1, 2025, alleging employment retaliation for reporting gender discrimination against female scientists.
5
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. Information regarding fair-trade certifications, audit frequency, substantiated forced or child labor incidents in the supply chain, supply chain traceability, remediation speed with specific timelines, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend was not available.
1
While the company states it does not employ individuals under 18 and prohibits forced labor within its own operations, and expects suppliers to comply with ethical standards, these statements do not provide the specific, quantifiable data required by the rubric for supply chain performance or contractual coverage.
2
Honest & Fair Business
-20
The company has a comprehensive Whistleblower Policy for Accounting and Auditing Matters, which is communicated through its Code of Business Conduct and Ethics.
1
This policy includes an EthicsLine, a dedicated email address, and a website for confidential and anonymous reporting.
2
It explicitly states that retaliation against whistle-blowers will not be tolerated and will result in disciplinary action, including termination.
3
The Audit Committee is responsible for supervising and overseeing inquiries and investigations related to accounting and auditing concerns.
4
The company also has an Anti-Bribery/Anti-Corruption Policy, which is FCPA-compliant and covers international business laws.
5
Periodic training sessions are held to ensure employees comply with relevant laws, rules, and regulations, including those prohibiting bribery and corruption.
6
However, the effectiveness of this training is not publicly measured.
Kind to Animals
-40
The company conducts animal testing for its medical products, services, research, and therapies, including in vivo studies to analyze immune responses.
1
These studies involve mouse models and rhesus macaques for SARS-CoV-2 infection.
2
Animal studies are carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and protocols are approved by Institutional Animal Care and Use Committees (IACUC) at various institutions.
3
Viral inoculations are performed under anesthesia, and efforts are made to minimize animal suffering.
4
A specific study mentioned used 12 rhesus macaques.
5
The company's research agreement mandates that the care and use of live vertebrate animals conform to the Public Health Service Policy on Humane Care and Use of Laboratory Animals, the Animal Welfare Assurance, the Guide for the Care and Use of Laboratory Animals, and USDA laws and regulations.
6
The agreement also states that federal funds will not be expended for research involving live vertebrate animals without approved assurance of compliance.
7
No War, No Weapons
-20
The company's Code of Business Conduct and Ethics, effective September 26, 2024, mentions compliance with U.S. Embargoes, which prohibit business with sanctioned countries and individuals.
1
Vir Biotechnology, Inc. supports the UN Universal Declaration of Human Rights and the United Nations Guiding Principles on Business and Human Rights, as stated in its Statement on Human Rights adopted by the CEO and executive management team on April 15, 2024, and effective April 19, 2024.
2
Planet-Friendly Business
-40
Vir Biotechnology conducted environmental assessments in 2022 and 2023.
1
The company is evaluating practices to reduce environmental impact, such as recycling, reducing waste, and saving energy.
2
A corporate environmental policy is planned for implementation in the coming year, and the company is committed to further developing a cohesive environmental program.
3
However, no specific, quantifiable data points are provided for other environmental KPIs, such as total emissions, renewable energy use, or waste diversion rates.
4
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess Vir Biotechnology, Inc. against the defined KPIs for 'Respect for Cultures & Communities'. The articles primarily focus on the company's partnerships with large foundations and research institutions, its drug development pipeline, and general information about clinical trials involving indigenous communities conducted by other entities. There is no direct evidence regarding Vir's formal partnerships with indigenous or local community groups, revenue reinvestment in local communities, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, or any other specific metrics outlined in the rubric for this value.
Safe & Smart Tech
-50
The company provides moderate user data control options, which align with standard industry practices, but there is some friction in exercising these rights, such as the requirement to verify identity for requests.
1
The company's regulatory compliance is basic with major regulations, but with identified gaps, and it appears to take a reactive approach to new privacy requirements. For instance, the FDA revoked the Emergency Use Authorization (EUA) for sotrovimab in December 2024, and the company acknowledges its subjection to stringent privacy and information security laws, with potential for fines and penalties for non-compliance.
2
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Zero Waste & Sustainable Products. While general environmental assessments were conducted in 2022
1
and 2023
2
, and there are plans to establish a corporate environmental policy
3
and develop a cohesive environmental program
4
, these statements do not provide measurable outcomes or specific initiatives that can be scored against the rubric's quantitative thresholds for waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management performance, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education.